Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 3
1997 1
1998 10
1999 11
2000 12
2001 19
2002 27
2003 90
2004 97
2005 92
2006 92
2007 92
2008 84
2009 84
2010 74
2011 58
2012 54
2013 42
2014 34
2015 25
2016 23
2017 18
2018 12
2019 25
2020 11
2021 10
2022 14
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

1,047 results
Results by year
Filters applied: . Clear all
Page 1
Enfuvirtide.
Dando TM, Perry CM. Dando TM, et al. Drugs. 2003;63(24):2755-66; discussion 2767-8. doi: 10.2165/00003495-200363240-00005. Drugs. 2003. PMID: 14664654 Review.
Enfuvirtide is the first of a new class of drugs, the fusion inhibitors. ...The antiviral efficacy of enfuvirtide was maintained through to 48 weeks. At 24 and 48 weeks, the increase from baseline in the CD4+ cell count was significantly greater for patients receivi …
Enfuvirtide is the first of a new class of drugs, the fusion inhibitors. ...The antiviral efficacy of enfuvirtide was maintain …
Enfuvirtide.
Chen RY, Kilby JM, Saag MS. Chen RY, et al. Expert Opin Investig Drugs. 2002 Dec;11(12):1837-43. doi: 10.1517/13543784.11.12.1837. Expert Opin Investig Drugs. 2002. PMID: 12457443 Review.
Viral gp41 then undergoes a conformational change enabling fusion of both membranes, a critical step in the viral life cycle. Enfuvirtide is a synthetic peptide that binds to gp41, preventing the conformational change required for membrane fusion. Based on potent in vitro …
Viral gp41 then undergoes a conformational change enabling fusion of both membranes, a critical step in the viral life cycle. Enfuvirtide …
Enfuvirtide.
Lalezari JP, Luber AD. Lalezari JP, et al. Drugs Today (Barc). 2004 Mar;40(3):259-69. doi: 10.1358/dot.2004.40.3.820089. Drugs Today (Barc). 2004. PMID: 15148534 Review.
The pharmacokinetic profile of subcutaneously administered enfuvirtide allows for twice-daily administration, although the possibility of once-daily dosing has not been excluded. Phase II and III clinical studies conducted to date have confirmed that enfuvirtide is …
The pharmacokinetic profile of subcutaneously administered enfuvirtide allows for twice-daily administration, although the possibilit …
Enfuvirtide-Induced Cutaneous Amyloidosis.
Sundharkrishnan L, Pilkington DM, North JP. Sundharkrishnan L, et al. Cutis. 2021 Mar;107(3):E15-E16. doi: 10.12788/cutis.0211. Cutis. 2021. PMID: 33956616 No abstract available.
Enfuvirtide.
LaBonte J, Lebbos J, Kirkpatrick P. LaBonte J, et al. Nat Rev Drug Discov. 2003 May;2(5):345-6. doi: 10.1038/nrd1091. Nat Rev Drug Discov. 2003. PMID: 12755128 No abstract available.
Enfuvirtide: a review of its use in the management of HIV infection.
Oldfield V, Keating GM, Plosker G. Oldfield V, et al. Drugs. 2005;65(8):1139-60. doi: 10.2165/00003495-200565080-00007. Drugs. 2005. PMID: 15907147 Review.
Although injection-site reactions occurred almost universally in enfuvirtide recipients, they were rarely treatment-limiting. Enfuvirtide was otherwise generally well tolerated. ...Enfuvirtide is a novel antiretroviral that is effective in HIV-infected patien …
Although injection-site reactions occurred almost universally in enfuvirtide recipients, they were rarely treatment-limiting. Enfu …
Enfuvirtide: from basic investigations to current clinical use.
Joly V, Jidar K, Tatay M, Yeni P. Joly V, et al. Expert Opin Pharmacother. 2010 Nov;11(16):2701-13. doi: 10.1517/14656566.2010.522178. Expert Opin Pharmacother. 2010. PMID: 20977403 Review.
Resistance to enfuvirtide is conferred by mutations in the HR1 region of gp41. Single and double mutations have been shown to result in high-level resistance to enfuvirtide. Postmarketing studies have been helpful to define more precisely the place of enfuvirtide …
Resistance to enfuvirtide is conferred by mutations in the HR1 region of gp41. Single and double mutations have been shown to result …
Enfuvirtide (T-20): potentials and challenges.
Foy K, Juethner SN. Foy K, et al. J Assoc Nurses AIDS Care. 2004 Nov-Dec;15(6):65-71. doi: 10.1177/1055329003256414. J Assoc Nurses AIDS Care. 2004. PMID: 15538017 Review.
Enfuvirtide is a fusion inhibitor used for the treatment of HIV infection. ...Enfuvirtide is well tolerated, and no limiting pharmacokinetic interactions have been published thus far. ...
Enfuvirtide is a fusion inhibitor used for the treatment of HIV infection. ...Enfuvirtide is well tolerated, and no limiting p …
Enfuvirtide: a novel agent for the treatment of HIV-1 infection.
Duffalo ML, James CW. Duffalo ML, et al. Ann Pharmacother. 2003 Oct;37(10):1448-56. doi: 10.1345/aph.1D143. Ann Pharmacother. 2003. PMID: 14519027 Review.
OBJECTIVE: To review the pharmacology, virology, pharmacokinetics, efficacy, safety, and clinical use of enfuvirtide. DATA SOURCES: English-language MEDLINE and AIDSline searches were performed (1966-January 2003) using enfuvirtide, T-20, gp41, and fusion inhibitors …
OBJECTIVE: To review the pharmacology, virology, pharmacokinetics, efficacy, safety, and clinical use of enfuvirtide. DATA SOURCES: E …
Enfuvirtide: first fusion inhibitor for treatment of HIV infection.
Jamjian MC, McNicholl IR. Jamjian MC, et al. Am J Health Syst Pharm. 2004 Jun 15;61(12):1242-7. doi: 10.1093/ajhp/61.12.1242. Am J Health Syst Pharm. 2004. PMID: 15259753 Review.
The recent approval of enfuvirtide offers a new and fourth class of antiretroviral agents called fusion inhibitors. Enfuvirtide is indicated for use in treatment-experienced patients who have evidence of viral replication despite receiving current therapy. ...
The recent approval of enfuvirtide offers a new and fourth class of antiretroviral agents called fusion inhibitors. Enfuvirtide …
1,047 results